Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Depression is known to occur frequently in chronic hepatitis C viral (HCV) patients receiving interferon (IFN)-α therapy. In this study, we investigated whether indoleamine 2,3-dioxygenase1 (IDO1)-mediated tryptophan (TRP) metabolism plays a critical role in depression occurring as a side effect of IFN-α therapy. Increases in serum kynurenine (KYN) and 3-hydroxykynurenine (3-HK) concentrations and in the ratios of KYN/TRP and 3-HK/kynurenic acid (KA) were much larger in depressive HCV patients than in non-depressed patients following therapy. Furthermore, transfection of a plasmid continuously expressing murine IFN-γ into normal mice significantly increased depression-like behavior. IFN-γ gene transfer also resulted in a decrease in serum TRP levels in the mice while KYN and 3-HK levels were significantly increased in both serum and frontal cortex. Genetic deletion of IDO1 in mice abrogated both the increase in depression-like behavior and the elevation in TRP metabolites’ levels, and the turnover of serotonin in the frontal cortex after IFN-γ gene transfer. These results indicate that the KYN pathway of IDO1-mediated TRP metabolism plays a critical role in depressive symptoms associated with IFN-α therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Changes in the levels of serum TRP and its metabolites in HCV patients undergoing IFN-α therapy. (a) The Y axis shows TRP, KYN, KA, and 3-HK concentrations in HCV patients at 2 and 4 weeks after the onset of therapy, expressed as a percentage of the concentration before IFN-α therapy. (b) Serum KYN/TRP and 3-HK/KA ratios in HCV patients are shown as a percentage of values before IFN-α therapy. Rectangles indicate non-depressive HCV patients [Depression (−)]; circles indicate HCV patients with depressive symptoms [Depression (+)]. Each data point represents the mean ± SEM of values obtained from n = 30 depression (−) patients and n = 19 depression (+) patients. *p < 0.05, ***p < 0.001 versus before the onset of IFN-α therapy, #p < 0.05, ##p < 0.01 versus depression (−) patients. Detailed statistical analyses are in Tables 2 and 3.](https://figures.cochat.ai/paper-figures/beb67d41022e4d23b84247a8c493d262/depressive-symptoms-as-a-side-effect-of-interferon-therapy-induced-by-induction-figure-1.jpg)
![Figure 2 Abnormal behavior in a forced swimming test after IFN-γ gene transfer in mice. The open bar shows control plasmid (empty pCpG-mcs vector)-injected mice [IFN-γ transfected (−) mice]; closed bar shows mice received the pCpG-Muγ plasmid, which continuously expresses murine IFN-γ [IFN-γ-transfected (+) mice]. (a) Locomotor activity and rearing of IFN-γ-transfected (+) and (−) mice in a novel environment in an open field test. (b) Short-term memory in a Y-maze test for the two groups of mice. Alternation behavior and total arm entries were measured in an 8 min session. (c) Immobility of IFN-γ-transfected (+) and (−) mice in a forced swimming test. Each column represents the mean ± SEM (n = 9–16). *p < 0.05 versus IFN-γ-transfected (−) mice.](https://figures.cochat.ai/paper-figures/e796bd300f184da5b0b547e656051dea/depressive-symptoms-as-a-side-effect-of-interferon-therapy-induced-by-induction-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The treatment of physical disorders, e.g., interferon-based or virostatic treatments for hepatitis C (167, 197), chemotherapy for the treatment of cancer (168), surgery (169) or transplantation (170), can lead to additional cytokine release.”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [197]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Behavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 4,013
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA
Liu, F., Song, Y. K., & Liu, D. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300947 · Cited by 1,727
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
O'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Hepatitis C: the clinical spectrum of disease.
Hoofnagle, J. H. (1997) · Hepatology · doi:10.1002/hep.510260703 · Cited by 765
Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism
Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb03460.x · Cited by 761
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Self-citationO'Connor, J. C., André, C., Wang, Y., Lawson, M. A., Szegedi, S. S., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5032-08.2009 · Cited by 502
Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445
Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., & Maes, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00014 · Cited by 437
Foster, A. C., Vezzani, A., French, E. D., & Schwarcz, R. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90050-8 · Cited by 434
Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Dieperink, E., Willenbring, M., & Ho, S. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.867 · Cited by 422
Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Gulati, M., Thornton, A. J., Schultz, R. L., Valentine, A. D., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001119 · Cited by 313
O'Connor, J. C., Lawson, M. A., André, C., Briley, E. M., Szegedi, S. S., Lestage, J., Castanon, N., Herkenham, M., Dantzer, R., & Kelley, K. W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802722 · Cited by 295
Depressive-like behavior induced by tumor necrosis factor-α in mice
Kaster, M. P., Gadotti, V. M., Calixto, J. B., Santos, A. R. S., & Rodrigues, A. L. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.018 · Cited by 294
Savitz, J., Drevets, W. C., Smith, C. M., Victor, T. A., Wurfel, B. E., Bellgowan, P. S., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.194 · Cited by 272
Salazar, A., Gonzalez-Rivera, B. L., Redus, L., Parrott, J. M., & O'Connor, J. C. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.03.010 · Cited by 263
Molecules in focus: Indoleamine 2,3-dioxygenase
King, N. J. C., & Thomas, S. R. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.004 · Cited by 259
Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders
Fakhoury, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9152-z · Cited by 246
Elevated Brain Serotonin Turnover in Patients With Depression: Effect of Genotype and Therapy
Barton, D. A., Esler, M. D., Dawood, T., Lambert, E. A., Haikerwal, D., Brenchley, C., Socratous, F., Hastings, J., Guo, L., Wiesner, G., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.11 · Cited by 220
Plasma L -Tryptophan Concentration in Major Depressive Disorder: New Data and Meta-Analysis
Ogawa, S., Fujii, T., Koga, N., Hori, H., Teraishi, T., Hattori, K., Noda, T., Higuchi, T., Motohashi, N., & Kunugi, H. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08908 · Cited by 183
Reduction of Brain Kynurenic Acid Improves Cognitive Function
Kozak, R., Campbell, B. M., Strick, C. A., Horner, W., Hoffmann, W. E., Kiss, T., Chapin, D. S., McGinnis, D., Abbott, A. L., Roberts, B. M., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1107-14.2014 · Cited by 180
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma
Recht, M., Borden, E. C., & Knight, E. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2617 · Cited by 177
Asnis, G. M., & De La Garza, R. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000210099.36500.fe · Cited by 170
Role of Kynurenines in the Central and Peripherial Nervous Systems
Nemeth, H., Toldi, J., & Vecsei, L. (2005) · Current Neurovascular Research · doi:10.2174/1567202054368326 · Cited by 169
Lawson, M. A., Parrott, J. M., McCusker, R. H., Dantzer, R., Kelley, K. W., & O’Connor, J. C. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-87 · Cited by 161
Morikawa, O., Sakai, N., Obara, H., & Saito, N. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00187-3 · Cited by 160
Carlin, J. M., Borden, E. C., Sondel, P. M., & Byrne, G. I. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.7.2414 · Cited by 154
Kynurenines with Neuroactive and Redox Properties: Relevance to Aging and Brain Diseases
Reyes Ocampo, J., Lugo Huitrón, R., González-Esquivel, D., Ugalde-Muñiz, P., Jiménez-Anguiano, A., Pineda, B., Pedraza-Chaverri, J., Ríos, C., & Pérez de la Cruz, V. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/646909 · Cited by 151
Depression From Interferon Therapy in Patients With Hepatitis C
Miyaoka, H., Otsubo, T., Kamijima, K., Ishii, M., ONUKI, M., & Mitamura, K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1120 · Cited by 135
(1998) · PubMed · Cited by 121
Laugeray, A., Launay, J., Callebert, J., Surget, A., Belzung, C., & Barone, P. R. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.014 · Cited by 120
Kraus, M. R., Schäfer, A., Schöttker, K., Keicher, C., Weissbrich, B., Hofbauer, I., & Scheurlen, M. (2008) · Gut · doi:10.1136/gut.2007.131607 · Cited by 118
The Role of Indoleamine 2,3-Dioxygenase in a Mouse Model of Neuroinflammation-Induced Depression
Dobos, N., de Vries, E. F. J., Kema, I. P., Patas, K., Prins, M., Nijholt, I. M., Dierckx, R. A., Korf, J., den Boer, J. A., Luiten, P. G. M., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111097 · Cited by 118
Lalonde, R., & Strazielle, C. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.02.003 · Cited by 108
Kamata, M. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00067-x · Cited by 105
Viral hepatitis: New data on hepatitis C infection
Szabó, E., Lotz, G., Páska, C., Kiss, A., & Schaff, Z. (2003) · Pathology & Oncology Research · doi:10.1007/bf02893380 · Cited by 100
Lawson, M. A., Kelley, K. W., & Dantzer, R. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.006 · Cited by 89
Mouri, A., Sasaki, A., Watanabe, K., Sogawa, C., Kitayama, S., Mamiya, T., Miyamoto, Y., Yamada, K., Noda, Y., & Nabeshima, T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6458-11.2012 · Cited by 88
Self-citationJohansson, A., Owe‐Larsson, B., Asp, L., Kocki, T., Adler, M., Hetta, J. E., Gardner, R. M., Lundkvist, G. B. S., Urbańska, E. M., & Karlsson, H. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.08.008 · Cited by 80
Pretreatment symptoms and dosing regimen predict side‐effects of interferon therapy for hepatitis C
Cotler, Wartelle, Larson, Gretch, Jensen, & Jr, C. (2000) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2000.00215.x · Cited by 76
Hattori, K., Nishikawa, M., Watcharanurak, K., Ikoma, A., Kabashima, K., Toyota, H., Takahashi, Y., Takahashi, R., Watanabe, Y., & Takakura, Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900215 · Cited by 69
Self-citationMitsui, M., Nishikawa, M., Zang, L., Ando, M., Hattori, K., Takahashi, Y., Watanabe, Y., & Takakura, Y. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1317 · Cited by 63
Self-citationFischer, C. W., Eskelund, A., Budac, D. P., Tillmann, S., Liebenberg, N., Elfving, B., & Wegener, G. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.015 · Cited by 62
Neuropsychiatric Effects and Type of IFN-α in Chronic Hepatitis C
Malaguarnera, M., Laurino, A., Di Fazio, I., Pistone, G., Castorina, M., Guccione, N., & Rampello, L. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/107999001300177457 · Cited by 57
Kobayashi, N., Nishikawa, M., & Takakura, Y. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.006 · Cited by 57
Self-citationAlkam, T., Kim, H., Mamiya, T., Yamada, K., Hiramatsu, M., & Nabeshima, T. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3175-9 · Cited by 56
Self-citationComai, S., Cavalletto, L., Chemello, L., Bernardinello, E., Ragazzi, E., Costa, C., & Bertazzo, A. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.10.009 · Cited by 55
Bianchi, M., Bertini, R., & Ghezzi, P. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80705-8 · Cited by 46
Species and Cell Types Difference in Tryptophan Metabolism
Murakami, Y., & Saito, K. (2013) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s11558 · Cited by 45
Self-citationSullivan, G. M., Oquendo, M. A., Huang, Y., & Mann, J. J. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006231 · Cited by 44
Fontana, R. J., Kronfol, Z., Lindsay, K. L., Bieliauskas, L. A., Padmanabhan, L., Back-Madruga, C., Lok, A. S. F., Stoddard, A. M., & the HALT-C Trial Group (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02106.x · Cited by 43
Developments in the treatment of chronic hepatitis C
Pockros, P. J. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.4.515 · Cited by 41
Vécsei, L., & Beal, M. F. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90043-h · Cited by 38
Iida, R., Saito, K., Yamada, K., Basile, A. S., Sekikawa, K., Takemura, M., Fujii, H., Wada, H., Seishima, M., & Nabeshima, T. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.7.1023 · Cited by 32
Self-citationInduction of Indoleamine 2,3-Dioxygenase in Human Cells in Vitro
Werner‐Felmayer, G., Werner, E. R., Fuchs, D., Hausen, A., Reibnegger, G. J., & WACHTER, H. (1991) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5952-4_55 · Cited by 21
Teraishi, T., Hori, H., Sasayama, D., Matsuo, J., Ogawa, S., Ota, M., Hattori, K., Kajiwara, M., Higuchi, T., & Kunugi, H. (2015) · Scientific Reports · doi:10.1038/srep15994 · Cited by 19
Cited by
Cytokine Research in Depression: Principles, Challenges, and Open Questions
Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00030 · Cited by 313
Tryptophan in health and disease
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.08.005 · Cited by 294
Type I interferon pathway in CNS homeostasis and neurological disorders
Blank, T., & Prinz, M. (2017) · Glia · doi:10.1002/glia.23154 · Cited by 165
The effects of vitamin B on the immune/cytokine network and their involvement in depression
Mikkelsen, K., Stojanovska, L., Prakash, M. D., & Apostolopoulos, V. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.11.012 · Cited by 169
The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis
Baumgartner, R., Forteza, M. J., & Ketelhuth, D. F. J. (2019) · Cytokine · doi:10.1016/j.cyto.2017.09.004 · Cited by 145
Metadata
- Authors
- Murakami, Y., Ishibashi, T., Tomita, E., Imamura, Y., Tashiro, T., Watcharanurak, K., Nishikawa, M., Takahashi, Y., Takakura, Y., Mitani, S., Fujigaki, H., Ohta, Y., Kubo, H., Mamiya, T., Nabeshima, T., Kim, H.-C., Yamamoto, Y., & Saito, K.
- Affiliations
- Doshisha University (JP)
- Kyoto University (JP)
- Gifu Municipal Hospital (JP)
- Hiroshima International University (JP)
- Fujita Health University (JP)
- Japanese Drug Organization of Appropriate Use and Research (JP)
- Kangwon National University (KR)
- Corresponding author
- Murakami, Yuki
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-07-20
- Volume
- 6
- Issue
- 1
- Pages
- 29920-29920
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4951771
- OpenAlex
- W2480881242
- Cited by
- 52
- References
- 62
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 7 · 2017: 7 · 2016: 2
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Smoking Research Foundation
- Japan Society for the Promotion of Science (15H03086, 26460675, 15H04100, 26860368, 24592734, 16K08948)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- depression, interferon-alpha therapy, IDO1, tryptophan metabolism, kynurenine pathway, chronic hepatitis C, interferon-gamma, kynurenic acid, serotonin turnover, depression-like behavior, frontal cortex, adverse drug reactions
- MeSH terms
- Animals, Behavior, Animal, Depression, Enzyme Induction, Female, Frontal Lobe, Humans, Interferon-gamma, Kynurenine, Male, Mice, Inbred C57BL, Middle Aged, Serotonin, Swimming, Tryptophan, Interferon-alpha, Hepatitis C, Chronic, Indoleamine-Pyrrole 2,3,-Dioxygenase, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.